Across TCGA pan-cancer cohorts, TRGV5 Mutation is linked to patient survival in 3 of 34 cancer types, making it a survival-associated TRGV5 data layer compared with 20 for mass-spec protein.
The strongest signal is observed in lung adenocarcinoma (LUAD), where higher TRGV5 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated TRGV5 expression acts as an unfavorable survival marker.
LUAD, ESCA, and STAD are the cancer types where TRGV5 Mutation most reproducibly stratifies survival.
Mutation survival associations by lineage
Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.